Krah D L, Amin R D, Nalin D R, Provost P J
Department of Cellular and Molecular Biology, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
J Infect Dis. 1991 Mar;163(3):634-7. doi: 10.1093/infdis/163.3.634.
A simplified hepatitis A virus (HAV) antigen-reduction neutralization assay (HAVARNA) was developed to permit the measurement of biologically active antibodies in recipients of candidate HAV vaccines. Degrees of neutralization were measured from the reduction in the amount of HAV antigen synthesized by 7-10 days after infection of MRC-5 (fetal human diploid lung) cell cultures. Sera producing a greater than or equal to 50% reduction in viral infectivity were scored as neutralizing. The assay was applied to demonstrate serum HAV neutralizing activity in 10 of 10 and 9 of 10 recipients of 10(7) and 10(6) TCID50 doses, respectively, of the Merck CR326F (F' variant) live attenuated vaccine. The dilution end points of selected sera ranged from 1:10 to 1:640. The dilution end point of the World Health Organization reference globulin no. 1 was 1:530,000 (0.2 mlU/ml of HAV antibody). The HAVARNA provided a rapid, sensitive, and reproducible means to measure neutralizing antibodies to HAV.
开发了一种简化的甲型肝炎病毒（HAV）抗原减少中和试验（HAVARNA），以测定候选甲型肝炎疫苗接种者体内的生物活性抗体。中和程度通过感染MRC-5（人胎儿二倍体肺）细胞培养物7至10天后合成的HAV抗原量的减少来测定。病毒感染性降低大于或等于50%的血清被判定为具有中和作用。该试验用于分别检测接种10（7）和10（6）半数组织培养感染剂量（TCID50）的默克CR326F（F'变异株）减毒活疫苗的10名接种者中的10名以及10名接种者中的9名的血清HAV中和活性。所选血清的稀释终点范围为1:10至1:640。世界卫生组织第1号参考球蛋白的稀释终点为1:530,000（0.2 mIU/ml的HAV抗体）。HAVARNA提供了一种快速、灵敏且可重复的方法来检测针对HAV的中和抗体。
